Taysha Gene Therapies, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Taysha Gene Therapies, Inc. (TSHA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 39.31 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- Taysha Gene Therapies, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 39.20M shares, a 26.92% increase year-over-year.
- Taysha Gene Therapies, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 30.88M shares, a 53.37% increase year-over-year.
- Taysha Gene Therapies, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 20.14M shares, a 225.86% increase year-over-year.
- Taysha Gene Therapies, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 6.18M shares, a 18.72% decline year-over-year.
- Taysha Gene Therapies, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 32.33M shares, a 42.67% increase from fiscal 2024.
- Taysha Gene Therapies, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 22.66M shares, a 175.43% increase from fiscal 2023.
- Taysha Gene Therapies, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.23M shares, a 9.68% increase from fiscal 2022.
- Taysha Gene Therapies, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.50M shares, a 27.60% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 39.31M shares 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 39.20M shares 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 32.33M shares 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 31.70M shares 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 31.84M shares 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 30.88M shares 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 22.66M shares 10-K · filed 2026-03-19 | |||
| 2024-09-30 | 85.07M shares 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | 21.10M shares 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | 20.14M shares 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 8.23M shares 10-K · filed 2025-02-26 | |||
| 2023-09-30 | 53.28M shares 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 9.27M shares 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | 6.18M shares 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 7.50M shares 10-K · filed 2024-03-19 | |||
| 2022-09-30 | 5.96M shares 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | 6.70M shares 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | 7.60M shares 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 5.88M shares 10-K · filed 2023-03-28 | |||
| 2021-09-30 | 5.81M shares 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | 5.74M shares 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | 5.91M shares 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | 4.29M shares 10-K · filed 2022-03-31 | |||
| 2020-09-30 | 3.80M shares 10-Q · filed 2020-11-12 | 3.80M shares 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | 6.20M shares 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | 6.00M shares 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |